Camargo Pharmaceutical Services to acquire Canada-based InSymbiosis
Date: 2019-06-15   Author: Paroma Bhattacharya  Category: #news

Camargo Pharmaceutical Services to acquire Canada-based InSymbiosis

Camargo Pharmaceutical Services, a leading drug development and commercialization service provider recently announced that it plans to acquire InSymbiosis, a Canada-based drug developer that enables biopharmaceutical companies to outsource research & development, cite sources.

The announcement came on the heels of an announcement made earlier this year by Camargo Pharmaceutical to expand its capabilities & global presence through acquisitions.

For the record, based in Montreal, Canada, InSymbiosis is managed by ex-pharma and contract research organization drug development executives and scientists. The company’s team includes financial and investment experts, a multidisciplinary drug development group and a competent project management team.

Dean Wenham, CEO, InSymbiosis was reported to say that the company started with a vision to build a mutual relationship across the healthcare landscape for pharmaceutical development. In partnership with Camargo, the synergy aims to deliver optimized development programs to clients and advance relationships across healthcare segment, Wenham added.

For the record, Camargo Pharmaceutical Services was founded in 2003 and is a global development & commercialization partner to large and small pharmaceutical companies. The company is known for its ability to provide life-changing therapies to clients, faster and more cost-effectively.

The company is established as a recognized expert & industry leader in designing complex, customized development strategies and focuses on client’s success. The client-base and global reach of Camargo extends to over more than 25 countries.

Dan Duffy, CEO, Camargo Pharmaceuticals was reportedly quoted saying that with the acquisition, the company will strengthen its ability to reach milestones & connect patients to life-changing therapies. InSymbiosis enables clients to optimize their clinical and non-clinical programs and provides excellent results.

Camargo Pharmaceuticals is better positioned in partnership with Insymbiosis to strengthen its efforts to deliver an industry-leading integrated drug development solution for the biotech and global pharma market, Duffy added.

Source credits: https://www.prnewswire.com/news-releases/camargo-pharmaceutical-services-enhances-drug-development-services-through-acquisition-of-montreal-based-insymbiosis-300866579.html



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Tata Steel to remove 3,000 employees from its Europe business
Author: Pankaj Singh

Tata Steel, a renowned Indian steel manufacturing company reportedly announced that it plans to cut 3,000 jobs from its European business. The move comes as a part of the company’s plan to put an end to the reduc...


Radpay’s valuation reaches $10.2 million after seed funding round
Author: Shikha Sinha

  • In a first, the company has secured funding from outside source
     
  • The two prominent investors included BlockLaunch and Resiliency Ventures
     
WeWork to lay off at least 4000 employees to reach financial stability
Author: Saipriya Iyer

WeWork, a renowned US-based commercial real estate firm, is reportedly planning to lay off more than 4,000 employees this month. Through this step, the company is looking to gain financial stability as it continues to ...